Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Australian National University, Australia
Australian National University, Division of Molecular Biosciences reports research in allergies gene therapy
November 7th, 2006
Current study results from the report, "Inhibition of arginase I activity by RNA interference attenuates IL-13-induced airways hyperresponsiveness," have been published. "Increased arginase I activity is associated with allergic disorders such as asthma. How arginase I contributes to and is regulated by allergic inflammatory processes remains unknown," scientists in Canberra, Australia report. "CD4+ Th2 lymphocytes (Th2 cells) and IL-13 are two crucial immune regulators that use STAT6-dependent pathways to induce allergic airways inflammation and enhanced airways responsiveness to spasmogens (airways hyperresponsiveness (AHR)). This pathway is also used to activate...
Source: Drug Law Weekly (2006-11-07)
|
